Literature DB >> 10792998

Synergistic interactions of antibodies in rate of virus neutralization.

P P Sanna1, F Ramiro-Ibañez, A De Logu.   

Abstract

Antibodies and antibody combinations are often evaluated only by their potency in inactivating a known quantity of virus in dose-effect assays. However, a crucial additional parameter is the rate at which neutralization takes place, or kinetics. Synergism of certain antibody combinations in dose-effect assays has been previously demonstrated. In the present report, using a battery of murine monoclonal antibodies to herpes simplex virus (HSV), we investigated whether antiviral antibodies can also synergize in neutralization kinetics. To determine whether synergism in dose-effect assays can predict synergism in neutralization rate, the ability of neutralizing antibodies to synergize in neutralization rate (kinetics) was compared to their ability to synergize in dose-effect assays (potency) in cell-free assays. Although certain antibody combinations synergized in both neutralization rate and potency, combinations that did not clearly synergize in potency could still significantly synergize in neutralization rate. Weak neutralizing antibodies could also greatly increase the neutralization rate of more potent antibodies. These results suggest that evaluating antibody combinations in dose-effect assays but not in neutralization kinetics provides a partial picture of neutralizing antibody dynamic interactions and may prevent the identification of certain favorable antibody combinations. These findings also support the importance of establishing defined antibody cocktails for prophylactic and therapeutic purposes. A simple strategy to evaluate antibody interactions in neutralization kinetics is proposed in which a quantitative prediction of additivity is made on the basis of the neutralization rate constants of the individual antibodies in the combination. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792998     DOI: 10.1006/viro.2000.0276

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  Using Split Luciferase Assay and anti-HSV Glycoprotein Monoclonal Antibodies to Predict a Functional Binding Site Between gD and gH/gL.

Authors:  Doina Atanasiu; Wan Ting Saw; Tina M Cairns; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2021-01-27       Impact factor: 5.103

2.  Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection.

Authors:  Ann R Hunt; Richard A Bowen; Shana Frederickson; Toshiaki Maruyama; John T Roehrig; Carol D Blair
Journal:  Virology       Date:  2011-04-13       Impact factor: 3.616

3.  Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization.

Authors:  Eric Lazear; J Charles Whitbeck; Manuel Ponce-de-Leon; Tina M Cairns; Sharon H Willis; Yi Zuo; Claude Krummenacher; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

4.  Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.

Authors:  Keith Meyer; Arnab Basu; Craig T Przysiecki; L Martin Lagging; Adrian M Di Bisceglie; Anthony J Conley; Ranjit Ray
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.